Glaukos Corp

Glaukos insider sells 1,074 shares at $97.02—an ordinary portfolio move, not a distress signal. Focus on its glaucoma drug pipeline, FDA milestones, and market dynamics for long‑term upside.

Glaukos insider trades reveal disciplined liquidity strategy amid promising GLO‑MIST trial results and FDA pre‑IND approval, hinting at future upside.